Alluvi, formerly BI 4744, represents a significant development in obesity therapy. This dual agonist targeting both GLP-1 and GIP receptors demonstrates compelling efficacy in research trials, possibly outperforming https://alluvi-healthcare161072.blog-kids.com/profile